| Basics |
Neurocrine Biosciences, Inc.
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
|
| IPO Date: |
May 23, 1996 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$15.51B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.85 | 1.95%
|
| Avg Daily Range (30 D): |
$1.62 | 1.12%
|
| Avg Daily Range (90 D): |
$1.61 | 1.15%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.69M |
| Avg Daily Volume (30 D): |
.91M |
| Avg Daily Volume (90 D): |
.77M |
| Trade Size |
| Avg Trade Size (Sh.): |
92 |
| Avg Trade Size (Sh.) (30 D): |
43 |
| Avg Trade Size (Sh.) (90 D): |
42 |
| Institutional Trades |
| Total Inst.Trades: |
11,970 |
| Avg Inst. Trade: |
$3.86M |
| Avg Inst. Trade (30 D): |
$8.84M |
| Avg Inst. Trade (90 D): |
$10.31M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$8.98M |
| Avg Closing Trade (30 D): |
$18.46M |
| Avg Closing Trade (90 D): |
$19.32M |
| Avg Closing Volume: |
97.42K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$2.11
|
$1.09
|
|
Diluted EPS
|
|
$2.04
|
$1.06
|
|
Revenue
|
$
|
$ 794.9M
|
$ 687.5M
|
|
Gross Profit
|
$
|
$ 780.9M
|
$ 676.2M
|
|
Net Income / Loss
|
$
|
$ 209.5M
|
$ 107.5M
|
|
Operating Income / Loss
|
$
|
$ 239M
|
$ 145.6M
|
|
Cost of Revenue
|
$
|
$ 14M
|
$ 11.3M
|
|
Net Cash Flow
|
$
|
$ 76.2M
|
$ 69.9M
|
|
PE Ratio
|
|
|
|
|
|
|
